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INTRODUCTION 
Portal hypertension can occur due to many reasons. One of the commonest 
causes for portal hypertension is cirrhosis. Other important causes are non 
cirrhotic portal fibrosis (NCPF) and extra hepatic portal vein obstruction 
(EHPVO). Portal pressure increases in cirrhosis initially as a result of an 
increased resistance to portal flow. This mostly results from fibrous tissue and 
regenerative nodules formation within the hepatic parenchyma which leads to 
distortion of the architecture of the liver.
1
 
 
Along with this structural resistance to blood flow, there is an intra-hepatic 
constriction of the vessels that accounts for twenty to thirty percent of the 
increase in resistance within the liver. This happens because there is decreased 
synthesis of nitric oxide endogenously. 
2-3
 The obstruction to the portal flow is 
at perisinusoidal level in NCPF but in EHPVO the obstruction is extra hepatic, 
which is commonly due to the formation of thrombosis in the portal vein. 
 
Porto-systemic collaterals are formed due to the development of portal 
hypertension. Although the collaterals are formed to relieve the portal pressure 
portal hypertension persists due to two causes: (1) an increase in portal venous 
inflow due to splanchnic arteriolar vasodilatation along with the formation of 
collaterals
4
 and (2) inadequate decompression of the portal venous system 
2 
 
through the collaterals since they have a higher resistance than the normal liver.
5
 
Therefore, an increased portal pressure gradient results from both an increase in 
portal blood inflow and increase in resistance to portal flow.     
 
Gastroesophageal varices are commonly seen in up to 50% of patients with 
cirrhosis.
6
 Gastric varices are seen in 20-25% of patients with portal 
hypertension.  If the patient is not having varices it will develop at the rate of 
8% per annum 
8-9
 and one who have small varices will develop larger varices at 
8% per year.. In few subsets of patients such as in primary biliary cirrhosis and 
hepatitis C with bridging fibrosis, even in the absence of overt cirrhosis they 
have propensity to develop varices in up to 16 % of the patients.
6-7
 Irrespective 
of the aetiology, the important and dreadful complication of varices is upper 
gastrointestinal bleeding.  
 
Prevalence of gastric varices is low when compared to esophageal varices. They 
are present in 6%-35% of patients with portal hypertension. The incidence of 
bleeding is about twenty-five percent in 2 years and highest bleeding rate is for 
fundal varices.
12
 Risk factors for gastric variceal haemorrhage include fundal 
varices size (large varices defined as >10 mm, medium -5-10 mm and small >5 
mm), Child-Turcotte-Pugh score, particularly Child C status and endoscopic 
presence of variceal red spots (defined as localized reddish mucosal area or 
spots on the mucosal surface of a varix).
 11, 13
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Gastric varices are classified into four types. The relationship of gastric varices 
with that of esophageal varices and the position in the stomach decides the 
gastroesophageal varices classification. Gastroesophageal varices (GOV) are 
classified into 2 types.  Type 1 gastroesophageal varices are called as GOV1 
which runs along the lesser curvature of the stomach and this most frequently 
seen. Since they are similar to esophageal varices, the management is same to 
that of esophageal varices. If the varices extend along the fundus, it is called as 
Type 2 gastroesophageal varices and tends to be longer and more tortuous. 
12
  
 
If gastric varices occur without the presence of esophageal varices they are 
categorized into two types. The first type is IGV1 are located in the fundus and 
tend to be tortuous and complex and type 2 (IVG2) are located in the body, 
antrum, or around the pylorus. The presence of IGV1 fundal varices requires 
excluding the presence of splenic vein thrombosis. 
 
In Indian study by Sarin et al, the incidence of gastric varices is just 4% in 
cirrhotics patient who has not bled. Others have shown that 25% of cirrhotics 
had gastric varices at screening endoscopy with 18% of patients having both 
gastric and esophageal varices.
12
 Gastric varices are also more common in 
NCPH and EHPVO which is present in 25% and 33% of patients respectively.
14
 
4 
 
The risk of bleeding with gastric varices is half that of esophageal varices. The 
transfusion requirement and mortality are high once the bleeding has occurred 
particularly for isolated gastric varices (IGV). Large gastric varices patients 
have a lower portal pressure compared to esophageal varices, which is due to 
the development of gastrorenal portosysytemic shunts, or large size of the 
varices resulting in increased wall tension.
15 
The type and prevalence of gastric 
varices varies greatly.  
 
5 
 
AIM 
 
The aim of this study is to assess 
1. The prevalence of gastroesophageal varices in patients with portal 
hypertension in a tertiary referral centre 
2. Characteristics of the gastric varices and  
3. Natural history of gastric varices in portal hypertension. 
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REVIEW OF LITERATURE 
 
Portal hypertension is an important and inevitable complication of cirrhosis of 
the liver, extrahepatic portal vein obstruction (EHPVO) and non cirrhotic portal 
fibrosis (NCPF), which leads to various hemodynamic effects. The portal 
pressure if an increase above 12 mm Hg is usually associated with portal 
hypertension and upper gastro intestinal bleeding can occur from varices in 
oesophagus, oesophagogastric junction, stomach, colon and other rare places 
such as duodenum. In colon, particularly it develops in the rectum. 
 
Gastric varices are commonly classified as GOVs (gastric varices in continuity 
with esophageal varices) and isolated gastric varices (IGV). Fifty percent of 
cirrhotic patients will have gastroesophageal varices and gastric varices are seen 
in approximately 20-25% of patients with portal hypertension.
12
 
 
The prevalence and risk of bleeding of gastric varices are lower than those of 
esophageal varices but bleeding from gastric varices tends to be more severe, 
requires more transfusions, and is associated with higher mortality (>45%) 
 
7 
 
Gastric varices tend to be larger and more tortuous compared with esophageal 
varices and along with their anatomical location (particularly fundic varices), 
make endoscopic management more challenging.  Current management 
strategies for gastric varices include pharmacotherapy which includes β-
blockers and vasoactive agents, endoscopic therapy (band ligation, thrombin, 
and tissue adhesives), transjugular intrahepatic portosystemic shunt (TIPS) 
placement; balloon occluded retrograde transvenous occlusion (BRTO) and 
ultimately surgical intervention in refractory cases. 
 
Natural History of Varices 
 
The important collaterals at the level of portosystemic circulation are 
esophageal and gastric varices. If they rupture, severe variceal hemorrhage can 
occur, the most catastrophic complication of cirrhosis. The direct complication 
of cirrhosis is the development of varices and bleeding, which is due to portal 
hypertension. Patients with cirrhosis and gastroesophageal varices have a 
hepatic venous pressure gradient of ten-twelve mm Hg.  
 
Severity of cirrhosis well correlates with the presence of gastric varices. They 
are present only 40% of Child A patients but 85% of Child C patients will have 
varices. If there is no varices at first visit in patients with cirrhosis, it will 
develop at a rate of eight percent per annum and the strongest predictor for 
8 
 
development of varices in those with cirrhosis who have no varices at the time 
of initial endoscopic screening is an HVPG >10 mmHg. 
 
Patients with small varices develop large varices at a rate of 8% per year. 
Decompensated cirrhosis (Child B/C), alcoholic cirrhosis, and presence of red 
wale marks (defined as longitudinal dilated venules resembling whip marks on 
the variceal surface) at the time of baseline endoscopy are the main factors 
associated with the progression from small to large varices. Variceal 
hemorrhage occurs at a yearly rate of 5%-15%, and the most important 
predictor of hemorrhage is the size of varices, with the highest risk of first 
hemorrhage (15% per year) occurring in patients with large varices. 
 
Although bleeding from esophageal varices ceases spontaneously in up to 40% 
of patients, and despite improvements in therapy over the last decade, it is 
associated with a mortality of at least 20% at 6 weeks.
16-18
 Patients with an 
HVPG  of >20 mmHg (measured within 24 hours of variceal hemorrhage) have 
been identified as being at a higher risk for early rebleeding (recurrent bleeding 
within the first week of admission) or failure to control bleeding (83% vs. 29%) 
and a higher 1-year mortality (64% vs. 20%) compared to those with lower 
pressure. 
19,20
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In approximately 60% of untreated patients late rebleeding occurs, mostly 
within 1-2 years of the index hemorrhage.
21-22
 Variceal wall tension is probably 
the main factor that determines variceal rupture. Vessel diameter is one of the 
determinants of variceal tension. At an equal pressure, a large diameter vessel 
will rupture while small diameter vessels will not rupture. Apart from the vessel 
diameter, one of the determinants of variceal wall tension is the pressure within 
the varix, which is directly related to the HVPG. 
23
 
 
A reduction in HVPG should lead to a decrease in variceal wall tension, thereby 
decreasing the risk of rupture. Indeed, variceal hemorrhage does not occur when 
the HVPG is reduced to ≤12 mmHg. It has also been shown that the risk of 
rebleeding decreases significantly with reductions in HVPG greater than 20% 
from baseline. 
24, 25
  
 
Patients whose HVPG decreases to ≤12mmHg or at least 20% from baseline 
levels (“HVPG responders”) not only have a lower probability of developing 
recurrent variceal hemorrhage, but also have a lower risk of developing ascites, 
spontaneous bacterial peritonitis, and death. 
26
  
 
 
 
10 
 
 
Gastric Varices 
 
Prevalence  
 
Gastric varix (GV) and its association with portal hypertension were first 
described in 1913.
27
 The prevalence of GV in patients with portal hypertension 
varies from 18% to 70%, although the incidence of bleeding from gastric 
varices is relatively low ranging from 10% to 36%. 
14, 15
  
 
In a study by Khalid Mumtaz et al, the prevalence of GV in patients with portal 
hypertension was 15% (220/1436) and the incidence of bleeding was 22.7% 
(50/220). Out of the 50 bleeding GV patients, isolated gastric varices (IGV-I) 
were seen in 22 (44%), gastro-oesophageal varices (GOV) on lesser curvature 
(GOV-I) in 16 (32%), and GOV on greater curvature (GOV-II) in 15 (30%). 
IGV-I was seen in 44% (22/50) patients who had bleeding as compared to 2 3% 
(39/170) who did not have bleeding (P < 0.003). 
28
 
 
Gastric varices are less prevalent than esophageal varices and are present in 5%-
33% of patients with portal hypertension with a reported incidence of bleeding 
of about 25% in 2 years, with a higher bleeding incidence for fundal varices. 
11 
 
 
In a study conducted by Sarin et al, the precise incidence of gastric varices in 
portal hyper tension is not known, but it has been reported to vary from 2-100 
%. Though it is generally believed that gastric varices bleed more severely than 
esophageal varices, the exact profile of bleeding of gastric varices in the 
presence or absence of esophageal varices is not known. 
 
Classification  
 
Sarin et al classified gastric varices based on their relationship with esophageal 
varices as well as their location in the stomach. Gastroesophageal varices 
(GOV) extend beyond the gastroesophageal junction and associated with 
esophageal varices and are divided into 2 types. The most common are Type 
1(GOV1) varices, which extend along the lesser curvature. They are considered 
extensions of esophageal varices and should be managed similarly. Type 2 
(GOV2) gastric varices extend along the fundus and tend to be longer and more 
tortuous.  
 
Isolated gastric varices (IGV) occur in the absence of esophageal varices and 
are also classified into 2 types. Type 1 (IGV1) are located in the fundus and 
tend to be tortuous and complex, and type 2 (IVG2) are located in the body, 
12 
 
antrum, or around the pylorus. The presence of IGV1 fundal varices requires 
excluding the presence of splenic vein thrombosis. 
 
 
 
Hashizume et al., described the type of gastric varices based on the clinically 
important findings during endoscopy, and especially from the view point of 
findings associated with the most risk of varices likely to rupture, similar to the 
classification of esophageal varices. He categorized the varices based on the 
findings of gastric varices in endoscopy and according to their form, location, 
and colour. 
29
 
 
 The form was classified into three types: tortuous (F1), nodular (F2), and 
tumorous (F3).  The location was classified into five types: anterior (La), 
posterior (Lp), lesser (Ll) and greater curvature (Lg) of the cardia, and fundic 
 
Figure-1. 
Sarin classification of 
gastroesophageal 
varices 
13 
 
area (Lf). The location of the gastric varices depends on hemodynamic factors. 
The colour can be white (Cw) or red (Cr). The glossy, thin-walled focal redness 
on the varix was defined as red colour spot (RC spot). The Hashizume Group 
reported that significantly higher risk of gastric variceal bleeding can occur 
from the RC spot and larger forms. 
 
 
 
A study by Ryan et al showed that GV also may be considered primary or 
secondary. Primary GV are those present at initial examination or in a patient 
who has never had EV endoscopic variceal sclerotherapy (EVS) or endoscopic 
variceal band ligation (EVL). Secondary GV refer to those that develop after 
endoscopic therapy (either EVS or EVL) for EV. 
30
 
Figure-2 Schematic diagram 
of endoscopic findings, 
classified by Hashizume et al 
14 
 
 
Endoscopic treatment of EV can have 2 distinct effects on GV. First, 
endoscopically evident GV develop in approximately 9% to 20% of patients 
previously treated with EVS or EVL for EV 
12, 31, 35
, but using more sensitive 
techniques such as endoscopic ultrasonography, they have been reported in 26% 
to 43% of patients so treated. 
34
 Second, esophageal EVS also can obliterate 
associated GV (GOV) in a large proportion of patients, depending on the GV 
type. 
12, 36, 37
  
 
Esophageal EVS led to the disappearance of 30% to 60% of GOV1
12, 31
 and 
20% of GOV2 within 6 months.  This is likely to be caused by caudal flow of 
sclerosant toward the GV. 
32, 40, 41
  Because of the possibility that GOV1 or 
GOV2 may disappear after esophageal EVS, it has been recommended that in 
patients with GOV1/2, the EV should first be treated,  and  if  after  6  months  
the  GV  persist,  then specific  therapy  for  the  GV  should  be  considered  if 
indicated. 
12,33
 
 
Hemodynamics  
In portal hypertension there is a generalized enlargement of the veins draining 
the digestive tract. 
42-44
 In the upper gastrointestinal tract the increased portal 
pressure is transmitted through two main venous pathways. First, through the 
right and left gastric veins, which drain varices around the distal oesophagus 
15 
 
and cardia (EV and GOV1) into the portal vein, or if the flow is reversed, the 
blood flows into the azygous system in cephalad direction.
15, 29
 
 
The second pathway is via the short and posterior gastric veins, which under 
normal circumstances drain blood from the fundus into the splenic vein. In 
portal hypertension the flow often is reversed and blood drains from the spleen 
toward the stomach into fundal varices (GOV2 and IGV1).
15
 IGV2 often are 
caused by dilation of branches of the gastroepiploic veins. 
 
 
 
An essential difference between EV and GV is their position in the 
gastrointestinal wall.  EV  form  in  the lamina propria mucosae and submucosa 
and GV lie deep in  the  submucosa  under  the  gastric  mucosa,  which  is 
relatively thick compared with that of the oesophagus.
45
   
Figure- 3 
Showing the type 
of gastric varices 
and their 
corresponding 
venous drainage 
a). GOV1, b) 
GOV2 and IGV1 
16 
 
 
 
 
 
Spontaneous portosystemic splenorenal or gastrorenal shunts commonly 
develop between the splenic vein (splenorenal shunt) and gastric varices, 
respectively, and connect via the inferior phrenic or suprarenal vein to the left 
renal vein.
15
  Such shunts, collectively termed gastrorenal shunts (GRS), are 
Figure – 4 (A) Normal portal 
venous blood ﬂow. PV, 
portal vein; COV,coronary 
vein; SPV, splenic vein; 
SMV, superior mesenteric 
vein. 
 (B) Portal venous blood 
ﬂow in the presence of portal 
hypertension and GRS. 
 Note reversal of flow in the 
coronary vein resulting in 
esophageal varices, and 
reversal of flow in the 
splenic vein resulting in 
gastric varices, which 
decompress via the GRS.  
LKID, left kidney; LRV, 
leftrenal vein; IVC, inferior 
vena cava. 
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more common in GV (60% to 85% of cases) than EV (17% to 21% of cases). 
15, 
46
 
 
Precisely what determines the predominant collateral pathways that develop in a 
given individual with PHT remains unknown, however, the size and length of 
the potential collateral vessel are likely to play a role.
15, 33
  Watanabe et al. 
found that 78% of patients with PHT had predominant collateral flow though 
the left or right gastric vein, which correlated with the presence of EV or 
GOV1, while a minority of patients had predominant collateral flow through the 
short and posterior gastric veins, correlating with the presence of GV.  
 
These frequencies of flow patterns are in good agreement with the observed 
frequencies of EV and GV.  Another study described blood flow patterns in 
patients with PHT based on the direction of flow in the left gastric vein and the 
presence or absence of a spontaneous GRS. 
46
  
 
Due to the portal and systemic hyperdynamic state in patients with portal 
hypertension gastroesophageal varices develop as one part of the circulation 
which is formed by collaterals. Till date, to whom the varices develop is 
questionable and it is largely unknown. The layer at which the varices develop 
is submucosal layer at the fundus or cardia of the stomach. The location of the 
varices in all cases goes along with the porto-systemic shunting boundary line.  
18 
 
 
This is due to relationship of the retroperitoneum with that off posterior wall of 
the cardiac or the fundic area, which  is fixed to the and lies  closest site to the 
systemic circulation via porto-systemic shunts. The hyperdynamic state of 
portal hypertension is characterized by the existence of either or both higher 
arterial and venous inflow. The higher venous outflow vessels associated with a 
major decrease in peripheral vascular resistance.  
 
The left gastric vein, posterior and short gastric veins are the main supplying 
vessels to gastric varices, while the gastro-renal shunt is the main drainage 
vessel. It is important to confirm the supplying vessels and the drainage vessels 
for the management of the gastric varices. Local hemodynamics of the gastric 
varices is very important in selecting the best choice for the effective treatment 
of the gastric varices.  
 
The diameter of huge gastro-renal shunt is about one to three centimetres. The 
volume of blood flowing through the shunt and the velocity of the porto-
systemic shunt are extraordinarily large. This is one reason why conventional 
endoscopic injection sclerotherapy (EIS) is usually not sufficient to obliterate 
the varices and can lead to serious complications such as pulmonary embolism 
or massive ulcer bleeding.  
 
19 
 
Recently, multidirection-computer tomography (MD-CT) provides the precise 
information such as the vascular architecture of the gastric varices without 
angiography
47, 48
 to know the hemodynamics of the portal circulation, including 
the supply and the drainage vessels and it is very helpful in selecting the best 
treatment choice for each patient with gastric varices.  
 
In patients, especially in Japan with gastrorenal shunts, balloon-occluded 
retrograde transvenous obliteration (B-RTO) is the most promising and the most 
effective treatment although it is mostly applied to prophylactic cases. 
49-51
  
 
Rick factors 
Precisely it is unclear what triggers a bleed from gastric varices. In EV, a 
decrease in varix wall thickness and an increase in diameter predispose to 
rupture.
52-54
 Similar factors are likely to be at play in GV but the overlying 
gastric mucosa is much thicker.  Although fundal varices   form   in   the   
submucosa,   they   do   penetrate through the muscularis mucosae and lamina 
propria at sites where they protrude into the stomach lumen; these vulnerable 
positions are where rupture occurs, possibly triggered by a mechanical insult or 
an ulcer overlying the GV, although this remains unproven.  
 
Few studies have prospectively examined the risk for bleeding and mortality 
from GV.
12, 13
 In one study, the 2-year risk for bleeding from GV was 25%, 
20 
 
which is similar to the 20% to 40% two-year risk for bleeding from EV 
55
. GV 
bled more severely than EV, requiring signiﬁcantly more transfusions. Fundal 
varices, however, had a signiﬁcantly higher bleeding incidence (78% for IGV1 
and 55% for GOV2), than GOV1 and IGV2 (10%).  In other smaller studies 
also similar bleeding rates were found. 
56
  
 
A number of risk factors for GV bleeding have been identiﬁed, they include:  
 
    1. Red color spots 
    2. Larger nodular GV 
    3. Fundal location.  
 
Kim et al 
13
 found that advanced Child–Pugh class, varix 5 mm or more in size, 
and the presence of a red spot were associated with an increased risk for a ﬁrst 
bleed.  In  that  study  the estimated 1-year risk for GV bleeding in patients 
ranged from  4%  to  65%  in  the  lowest  risk  and  highest  risk categories,  
respectively. Factors not associated with bleeding risk included classification as 
primary or secondary, concomitant EV, underlying cause of liver disease, and 
presence of encephalopathy, among others. A PPG of ≥12 mm Hg is not 
necessary for development of, or bleeding from, GV.  
 
 
21 
 
Clinical presentation: 
GV are discovered most commonly during screening of PHT patients for 
varices, or at the time of a first variceal bleed, at which time the bleeding 
usually is caused by associated EV and uncommonly originates from bleeding 
GV.
12
 Considerable number of patients with GV also may present with hepatic 
encephalopathy. Watanabe et al. showed that encephalopathy was more 
common in GV (25%) than EV (3%) patients, probably attributable to the 
increased prevalence of GRS in GV patients.
15 
 
Diagnosis 
There are various methods to diagnose the gastric varices namely upper 
gastrointestinal endoscopy, ultrasonography, computed tomography, magnetic 
resonance imaging and endoscopic ultrasonography. 
 
Upper Gastrointestinal Endoscopy  
Upper endoscopy is usually the initial investigation in patients with suspected 
fundal varices although the distinction between fundal varices and gastric folds, 
particularly in patients with hypertensive gastropathy may be difficult. The 
current consensus is that all patients with cirrhosis of the liver, extrahepatic 
portal vein obstruction and non cirrhotic portal fibrosis should be screened for 
esophageal varices by endoscopy. In patients in whom no varices are detected 
22 
 
on initial endoscopy, endoscopy to look for varices should be repeated in 2 to 3 
years.  
If small varices are detected on the initial endoscopy, endoscopy should be 
repeated in 1 to 2 years.
57, 58 
None of the various non-invasive methods of 
determining which patients benefit most from endoscopic screening are accurate 
enough to recommend for routine use in clinical practice.
59 
The role of non-
invasive markers in predicting the risk of large gastroesophageal varices 
requires study in large multicenter trials.
60
 Preliminary data suggest that 
wireless video capsule endoscopy and computed tomography (CT) imaging are 
alternative screening modalities in patients who are not candidates for upper 
endoscopy. Moreover, CT screening may be more cost-effective than 
endoscopy. 
61
 
Gastroesophageal varices are diagnosed on retroflexion during upper 
gastrointestinal endoscopy and classified according to Sarin. 
Ultrasonography  
Ultrasound examination of the liver with Doppler study of the vessels has been 
used widely to assess patients with portal hypertension. Features suggestive of 
portal hypertension on ultrasonography include splenomegaly, portosystemic 
collateral vessels, and reversal of the direction of flow in the portal vein 
(hepatofugal flow). Few studies have demonstrated that a portal vein diameter 
23 
 
greater than 13 mm and the absence of respiratory variations in the splenic and 
mesenteric veins are sensitive but nonspecific markers of portal hypertension. 
62, 
63
 
These criteria are not used routinely in clinical practice in most centres. 
Ultrasound examination can detect thrombosis of the portal vein, which appears 
as nonvisualization or cavernous transformation (a cavernoma) of the portal 
vein; the latter finding indicates an extensive collateral network in place of the 
portal vein.
64
 Splenic vein thrombosis also can be demonstrated. Portal blood 
flow can be measured by Doppler ultrasonography, which is the easiest research 
method for detecting postprandial increases in splanchnic blood flow .
65 
Although Doppler ultrasonography is clinically useful in the initial evaluation of 
portal hypertension, the technique is not widely used to provide quantitative 
assessments of the degree of portal hypertension. Transient elastography may be 
useful in detecting portal hypertension but is not sufficiently sensitive to 
recommend as a modality to monitor decreases in portal pressure in patients on 
pharmacotherapy.
66
 
Computed Tomography  
Computed tomography (CT) is useful for demonstrating many features of portal 
hypertension, including abnormal configuration of the liver, ascites, 
splenomegaly, and collateral vessels. Detection of varices may be an emerging 
24 
 
indication for CT. Diagnosis of fundal varices by multidetector row CT 
(MDCT) is at least as accurate as endoscopic ultrasonography. 
CT is especially helpful in distinguishing submucosal from perigastric fundal 
varices 
67 
and is considered a less invasive alternative to conventional 
angiographic portography in assessing portosystemic collaterals. At present, 
however, CT is not a recommended screening method for detecting large 
esophageal varices, but it may be a cost-effective method of screening for 
varices and preferred to endoscopy by patients.
61
 
The computed tomography (CT) angiography is gaining increasing acceptance 
as a minimally invasive technique for imaging the abdominal vascular system, 
which allows visualization of small visceral vessels by offering shorter 
acquisition times, less motion artefacts and increased spatial resolution.
51, 68, 69
  
 
These features may be useful in order to assess the gastric fundus for the 
presence and differentiation of submucosal and perigastric varices. In a study by 
Willmann et al, it is mentioned that Multi-detector row CT (MDCT) 
angiography is gaining increasing acceptance as a minimally invasive technique 
for imaging the abdominal vascular system.
67
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Magnetic Resonance Imaging  
Gadolinium-enhanced magnetic resonance imaging (MRI) is becoming 
recognized as a potentially useful method of detecting esophageal varices.
70 
In 
addition, MRI can be used to measure portal and azygous blood flow, which is 
increased in patients with portal hypertension.
71 
MRI provides excellent detail 
of the vascular structures of the liver and can detect portal venous thrombosis 
and spleen stiffness in patients with portal hypertension, but the role of MRI in 
the assessment of portal hypertension requires further study. Unlike transient 
elastography using ultrasound, MRI can accurately assess the stiffness of even 
fatty livers.
72
 
Endoscopic Ultrasonography  
Currently, endoscopic ultrasound (EUS) is considered most useful in the 
evaluation and diagnosis of submucosal fundal varices which allows 
visualization of the different layers of the gastric wall and permits 
differentiation between submucosal and perigastric fundal varices.
73-75
 
However, EUS is invasive, not widely available, and examiner dependent. 
Hence a non-invasive imaging modality would be preferable in these high risk 
patients. 
Endoscopic ultrasound examination (EUS) using radial or linear array echo-
endoscopes or endoscopic ultrasound mini-probes passed through the working 
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channel of a diagnostic endoscope has been applied as an investigational tool in 
the evaluation of patients with varices.  
EUS can be combined with endoscopic measurement of transmural variceal 
pressure to allow estimation of variceal wall tension, which is a predictor of 
variceal bleeding.
76-78
  
Splenoportography or percutaneous transhepatic portography 
The role of splenoportography or percutaneous transhepatic portography is 
limited in the distinction between submucosal and perigastric fundal varices, 
although this modality allows good assessment of the portal venous system and 
its collaterals.
79
  
Management: 
Although  variety  of  treatments  have  been  developed  for  esophageal varices  
since  the  1940s  including  porto-caval  shunts,  selective shunts,  or  
esophageal  transaction,  as  well  as  endoscopic  treatments, the management 
of gastric varices still remains a therapeutic challenge. Most approaches have 
been performed successfully and clinical results have been acceptable when the 
indications have been appropriately applied. Because there are few controlled 
clinical trials, much less confidence can be placed on guidelines for the 
management of gastric varices than for their esophageal counterparts.
80
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Most   studies   that   have   investigated   the   effect   of β-blocker in primary 
prevention have contained few patients with GV.
81-85
 GOV1 seem to behave 
similarly to EV and should be treated accordingly. RCTs investigating β-
blockade in primary prophylaxis of GV bleeding need to be performed. 
However, until such time that conclusive data from RCTs suggest otherwise, it 
seems reasonable to give β-blockers empirically in primary prevention of GV 
bleeding, although their value is not proven. 
 
Since the mortality of GV hemorrhage is high, it has been suggested that the 
patients at high risk for bleeding with an annual risk of 16% 
86
 should undergo 
primary prophylactic eradication of the GV.
87
 Although this approach is 
embraced in Asia; it remains contentious and is not standard accepted practice 
in most western centres. Well-designed RCTs are required before this approach 
can be propounded universally.  
 
Management of Acute Bleeding and Prevention of Rebleeding  
 
Bleeding should be considered to have arisen from GV if there is (1) active 
spurt or ooze, (2) adherent clot, or (3) presence of large GV, no EV, and no 
other source of bleeding evident.
88
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The modalities of therapy available include the following: 
 
1. Pharmacotherapy & antiboitics 
2. Balloon tamponade with Sengstaken Blackmore or Linton Nachlas tube 
3. Endoscopic variceal sclerotherapy 
4. Endoscopic variceal obturator therapy with N-Butyl-2- Cyanoacrylate 
and thrombin 
5. Endoscopic variceal ligation using snares, bands and endoloops  
6. Endoscopic variceal ligation–injection sclerotherapy  
7. Interventional radiology such as BRTO and TIPSS 
8. Shunt surgery 
 
 Pharmacotherapy 
 
 There  is  little  data  concerning  the  efficacy  of somatostatin  or  vasopressin  
or  their  analogues  in  the control of acute GV bleeding.
89
 However, given the 
similar pathophysiology and anatomy, GOV1 should be treated as for EV. 
Octreotide has been shown to have a beneficial effect on acute bleeding from 
portal hypertensive gastropathy, but it is likely that the often voluminous 
bleeding from GV might not be controlled by pharmacologic measures.
90
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The role of β-blockers and nitrates in secondary prevention of GV bleeding has 
not been studied extensively. A small open-label trial of -blocker and nitrate 
therapy reported that although these agents conferred no significant benefit in 
terms of risk for rebleeding or overall survival.  
 
Antibiotics  
Antibiotics  should  be  administered  as  early  as possible in acute variceal 
bleeding because, bacterial infection occurs in 20%  of  cirrhotic  patients 
91
 
within 2 days of an acute variceal bleed and  is  associated  with  a worsening of 
prognosis.
92,93
 Bacterial translocation may be spontaneous or due to 
instrumentation. A recent meta-analysis showed that antibiotic prophylaxis 
significantly reduced infection rates and was associated with a better short-term 
prognosis.
94
   
 
Fluoroquinolones such as ciprofloxacin  have  been  shown  to  signiﬁcantly  
reduce infection  in  several  studies.
95
  and  oral  or  intravenous ciprofloxacin 
prophylaxis at a dose of 1 g/day has been recommended.
89
  RCTs comparing 
systemic vs. oral nonabsorbable antibiotics are needed.
96
  
 
Balloon Tamponade  
The  commonly  used  Sengstaken–Blakemore  or Minnesota tubes are not 
usually efficacious in controlling bleeding   from   fundal   varices,   owing   to   
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the   small volume  of  the  gastric  balloon  (200  mL). The  Linton– Nachlas  
tube  has  a  600-mL  volume  single  gastric balloon  and  seems  to  be  more  
effective  in  controlling fundal variceal bleeding in up to 50% of patients, 
although  20%  subsequently  will  rebleed.
97,98
 Balloon tamponade should be 
used only as a stopgap to definitive treatment for gastric varices. 
 
Endoscopic Therapy 
 
Endoscopic Variceal Sclerotherapy (EVS)   
Traditional  endoscopic variceal  sclerotherapy involves  injection  of  
sclerosants  such  as  ethanolamine oleate  or  absolute  alcohol  intra-  or  
perivariceally  (or both) which  results in endothelial damage and thrombosis of 
blood  and  subsequent  sclerosis  of  the  varix.  This  has  been  very  
successful  in  the  treatment  of  EV bleeding and in eradication of EV.
99,100
 it 
has been less successful in the treatment of GV, probably because of the high-
volume blood flow through GV compared with EV, resulting in rapid flushing 
away of the sclerosant in the bloodstream.  
 
Typically, EVS of GV requires larger volumes of sclerosant than for EV, and 
fundal varices (GOV2 and IGV1) require signiﬁcantly more sclerosant than 
GOV1. This may be associated with more side effects after EVS for GV than 
for EV. The commonly seen side effects are retrosternal, abdominal pain and 
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fever.
101
.  In acute GV bleeding, EVS controlled bleeding in 60% to 100% of 
cases, depending on the report 
102
, but has been associated with unacceptably 
high rebleeding rates of up to 90%.  
 
It appears to be least successful in controlling acute fundal variceal bleeding.
103
 
Differences observed between studies may reflect different injection techniques, 
different mixes of GV subtypes, but also inclusion of different patient 
populations; half of the patients in one study had noncirrhotic PHT 
104
, whereas 
in the other studies more patients had cirrhosis and associated hepatic synthetic 
dysfunction. 
 
EVS achieved secondary prophylactic variceal eradication  in  40%  to  70%  of  
all  GV  patients  treated  electively 
105
,  but Sarin et al. found that this success 
was weighted heavily by high efficacy in GOV1 (95% eradication) and was less 
effective for GOV2 and IGV1. In that study, rebleeding after elective EVS was 
less than 20% for patients with GOV1 and GOV2 but it was high in patients 
with IGV1 (53%). Most bleeds were related to ulcers at the injection site 
reﬂecting the large amounts of sclerosant often needed.  
 
EVS is an effective and appropriate treatment for both treatment of acute GOV1 
hemorrhage and for attempting secondary prophylactic GOV1 obliteration. 
However it is not appropriate for patients with fundal varices (GOV2 or IGV1) 
32 
 
because of the low rate of primary hemostasis, the low success rate for 
secondary variceal eradication, and the high rate of rebleeding. 
 
Endoscopic  variceal  obturation  therapy:  
Endoscopic variceal obturation (EVO) refers to the injection of agents   such   
as  n-butyl-2-cyanoacrylate   (Histoacryl), isobutyl-2-cyanoacrylate (Bucrylate), 
or thrombin, which solidify  and/or  induce  thrombosis  in  the  varix 
106
  with 
ultimate sloughing off of the glue cast weeks to months post injection,  resulting  
in  late  ulceration.  At present, these agents are not approved for use in GV in 
many countries, but it is available in other countries including India and in a 
study by Khalid Mumtaz et al the success rate for achieving primary 
haemostasis with glue was 90-100% without recurrent bleeding within 48 hrs. 
The same result was also observed in a study in India conducted by Shiv K 
Sarin et al in acute GV bleeding.   
 
EVO has emerged as the initial treatment of choice for acute GV bleeding and 
for secondary eradication of GV. Two small RCTs have shown that EVO is 
superior to both EVS and EVL 107 in the treatment of acute GV bleeding, 
achieving haemostasis in 90% of cases compared with 62% for EVS 
107
and 40% 
for EVL.  Sarin et al. found a similar rebleeding rate (22% to 25%) in both EVS 
and EVO groups, but the overall success of EVO was better (78% vs. 38%) 
because of the higher rate of initial haemostasis. A number of large case series 
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or nonrandomized trials also have shown that cyanoacrylates successfully 
control acute GV bleeding in over 90% of cases.
108-111
  
 
Thrombin also has been used to control fundal variceal bleeding  with  a  
relatively  good  success  rate  of  up  to 75% 
112
  and a rebleeding rate of 0% to 
30% in the small  reported  series.  To date, no RCTs of thrombin injection 
therapy for bleeding GV have been performed. Eradication rates between 50% 
and 100% have been reported with an average of about 75%. In the long term, 
GV rebleeding occurs in 23% to 50% of patients, with the vast majority 
occurring in the first year.  
 
Side effects of EVO include pyrexia and abdominal discomfort, which are 
usually mild and transient.  Uncommon side effects associated with the use of 
acrylates include cerebral, pulmonary and portal vein embolism, retroperitoneal 
abscess, splenic infarction, and portal and splenic vein thrombosis. The 
systemic emboli probably occur in patients with large GRS and 
hepatopulmonary syndrome.  
 
Hepatopulmonary syndrome is found in up to 20% of patients with cirrhosis and 
is characterized by pulmonary microvasculature dilatation with consequent 
right-to-left shunting potentially facilitating entry of the glue-like substance into 
the systemic circulation. Avoidance of this technique in patients with known 
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large GRS or hepatopulmonary syndrome may help avoid embolic 
complications.  
 
Embolic and thrombotic phenomena have been associated with a larger volume 
of injected material and it is recommended that no more than 2 mL. of 
compound should be injected in a session.  Precautions to prevent damage to the 
scope must be taken when using this agents.
113
 Given the high rate of primary 
haemostasis and lower rate of rebleeding compared with EVS, EVO with 
acrylates is now used as standard first-line treatment of bleeding fundal GV and 
in secondary prophylactic eradication of GV.  
 
Endoscopic variceal ligation:  
 EVL with nylon or stainless steel snares or standard rubber bands has been 
used in treatment of bleeding GV. GV smaller than 2 cm in diameter can be 
ligated with standard rubber bands, whereas larger-diameter GV require the use 
of larger detachable snares. The literature is sparse on this topic and only one 
RCT has been reported comparing GV EVL using rubber bands against EVO.  
 
Barbera Ryan et al found that EVL was less effective than EVO in controlling 
acute GV (45% vs. 87%) and had a higher rebleeding rate (54% vs. 31%), 
although the ability to eradicate varices was similar (45% vs. 51%). A number 
of case series, however, have shown EVL to be safe and highly efficacious in 
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terms of achieving haemostasis in acute GV bleeding (83% to 100%), low 
rebleeding rate (0% to 19%), and eradication of GV (77% to 100%).
114
  
 
Active bleeding was controlled in 83% (10/12) of patients, one acute bleeder 
died and one bleeder required rescue EVO. The rebleeding rate was low and 
often was caused by ulceration at the ligation site.  GV were eradicated 
successfully in almost all patients initially, but all patients subsequently 
developed recurrent GV within 2 years. Most of the recurrences  were  treated  
with  EVO  or  EVS  owing  to difficulties  in  snaring  the  varices  in  fibrosed  
mucosa. 
 
Higher GV recurrence post-EVL compared with post- EVO may be owing to a 
lesser degree of deep fibrosis after EVL compared with EVO.
115
 Future  RCTs  
are  required  to compare  EVL  with  the  gold  standard  of  EVO  and  to 
define the long term outcome of this therapy. 
 
Endoscopic variceal ligation–injection sclerotherapy: 
A combination technique of EVS and EVL, called endoscopic variceal ligation 
injection sclerotherapy, has been reported by Japanese endoscopists.
116
 Using 
this technique, a detachable snare is placed around the varix and partially 
tightened to cause stasis of blood.   
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The sclerosant (ethanolamine oleate) is then injected into the varix, followed by 
tightening and release of the snare around the varix. Uncontrolled data from a 
total of 22 patients treated with endoscopic variceal ligation injection 
sclerotherapy for acute GV bleeding reported haemostasis in 100%, a low 
rebleeding rate of 0% to 8%, and a GV eradication rate of 85% up to 2 years 
posttreatment.
117
   
 
The better long-term eradication rates than EVL alone may reflect the added 
fibrosing effect of the sclerosant. 
 
Interventional Radiologic Treatment  
 
TIPSS- Transvenous intrahepatic portosystemic shunt therapy 
Most published series of TIPS contain relatively few GV patients. For 
management of EV bleeding,  meta-analysis  comparing  TIPS  with  
endoscopic treatment  has  shown  that  TIPS  is  associated  with  a reduction in 
rebleeding, a higher risk for encephalopathy,  and  a  similar  overall  survival  
rate.
118
  
 
British Society of Gastroenterology guidelines for the management of variceal 
hemorrhage in cirrhotic patients recommended TIPS or shunt surgery as second-
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line therapy for control of acute GV bleeding when standard endoscopic 
measures have failed. Appropriate patient selection for TIPS is critical.
89
 
 
Prognosis is worst in Child–Pugh class C, but the majority of candidates for 
TIPS fall within this category. Other factors shown to be associated with poor 
outcome after TIPS in patients with advanced liver disease include higher serum 
bilirubin and creatinine levels, underlying chronic viral hepatitis as opposed to 
chronic alcohol-induced cirrhosis, variceal hemorrhage necessitating emergent 
TIPS, and high international normalized ratios.
119
  
 
TIPS in acute GV bleeding.   
The current role of TIPS in acute GV bleeding is as second-line rescue therapy 
when EVO has failed. In GV, TIPS has been shown to control acute refractory 
GV bleeding in 90% to 100% of cases.
120
 Rebleeding occurs in 10% to 30% of 
patients within 1 year. Early rebleeding (within  the  first  week) and late 
rebleeding (after 1 week) can occur due to recurrent variceal bleeding and  stent 
failure (stenosis or occlusion) respectively. New-onset encephalopathy develops 
in 3% to 16% of patients after TIPS. 
 
After control of GV bleeding by TIPS, reported survival rates vary from 50% to 
85% at 1 month, to 58% to 79% at 1 year.
121
 The most common causes of 
mortality are sepsis, multiorgan failure, and recurrent hemorrhage.  
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TIPS for prevention of GV rebreeding. 
In an early study, Spahr et al. found that the post-TIPS rebleeding rate was 
higher from GV (53%) than from EV (11%).
122
 Stanley et al., however, found 
no difference in rebleeding from GV (13%) and EV (17%) during a follow-up 
period of approximately 1 year.  
 
An interesting finding of the study of Tripathi et al. concerns the role of PPG in 
GV and EV bleeding. They found that 35% of GV bleeders had a PPG of ≤12 
mm Hg at the time of TIPS compared with only 8% of EV patients. In patients 
who had pre-TIPS PPG of ≤12 mm Hg, a decrease in PPG after TIPS did not 
affect the risk for rebleeding, suggesting that in this subgroup of patients, PPG 
may not be the critical determinant of bleeding risk. In contrast, in the group in 
which pre-TIPS PPG was ≥12 mm Hg, a clear relationship was shown between 
post-TIPS risk for rebleeding and higher post-TIPS PPG, suggesting that in this 
group, PPG plays a central role in determining the risk for bleeding.
123
 
 
TIPS stent surveillance.   
Pseudointimal hyperplasia leading to stent occlusion is a major drawback of 
TIPS. Studies have shown that stent insufficiency occurs in 30% to 80% and 
47% to 90% of patients by 1 and 2 years post-TIPS, respectively. When clinical 
signs herald stent insufficiency, then clearly re-intervention is indicated.  The  
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optimal  post-TIPS  surveillance regimen has not yet been deﬁned and there are 
arguments  for  and  against  both  a  more-  or  less-invasive approach.
124
   
 
Doppler ultrasound is 70% sensitive and 90% specific in predicting stent 
dysfunction. Surveillance portal angiography every 6 months has been 
advocated.
124
 Computed tomography angiography and magnetic resonance 
angiography also offer excellent images of the portal vasculature and can be 
used to monitor the shunt anatomy (but not function) post-TIPS.
44
  
 
 TIPS is currently indicated for treating refractory GV bleeding and for 
prevention of rebleeding although further RCTs are required. One year post-
TIPS, the rebleeding rate is between 10% and 30%, the incidence of new-onset 
encephalopathy is 3% to 18%, and the overall 1-year survival ranges from 58% 
to 80%, depending mainly on the severity of the underlying liver disease. 
Appropriate patient selection is critical and the severity of the underlying liver 
disease must be taken into consideration.  
 
Balloon-Occluded Retrograde Transvenous Obliteration and Balloon-
Occluded Endoscopic Injection Sclerotherapy 
 
 A number of interventional radiologic techniques have been developed in Japan 
for the treatment of GV. These therapies have been used predominantly in 
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primary prophylactic GV eradication, but also to treat acute GV bleeding and in 
secondary preventive GV eradication.  
 
Primary GV eradication in patients with high-risk GV is not standard accepted 
practice outside Asia. To date, there is no experience of these techniques outside 
of Japan and almost all data emanate from case series. Balloon-occluded 
retrograde transvenous obliteration (B-RTO) is technically feasible only in 
patients with a known GRS, which accounts for almost 85% of GV patients.  
 
Treatment and short-term outcome of 188 patients treated with BRTO has been 
reported in the literature.
46
 Haemostasis was achieved in 100% (16/16) of 
patients for acute bleeding and the rebleeding rate was 0% during almost 2 
years of follow-up evaluation. The majority of literature, however, pertains to 
eradication of high-risk GV, for which B-RTO was reported to eradicate 85% to 
100% of GV and to have a low rate of rebleeding.  
 
The most common complications reported were hemoglobinuria, abdominal 
pain, transient fever, pleural effusion, and transient worsening in liver 
biochemistry, but more serious complications also have been reported including 
shock and atrial ﬁbrillation.  
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A potentially problematic long-term sequelae of B-RTO is the observed 
development or worsening of EV in up to 50% of patients thus treated, although 
on the whole EV are managed more easily than GV.
46
 Balloon-occluded 
endoscopic injection sclerotherapy, another vascular interventional technique 
developed in Asia,  can  be  performed  in  patients  with  or without  a  GRS,  
but  it  is  more  invasive.
125
  
 
Reports of fewer than 20 patients suggest that it is a potentially  effective  
means  of  eradicating  GV  and  it  seems  similar  to  B-RTO  in  terms  of  
safety  and  efficacy. RCTs comparing B-RTO and balloon-occluded 
endoscopic injection sclerotherapy with standard therapies for acute GV 
bleeding need to be performed.  
 
Surgery 
Portocaval shunts can be either nonselective (diversion of portal blood flow into 
the systemic circulation, bypassing the liver) or selective (such as distal 
splenorenal shunts (Warren) that drain varices into the systemic system without 
affecting liver blood ﬂow).  Most reported studies included mainly EV patients. 
A  meta-analysis  has  shown  that  although shunt surgery was associated with a 
signiﬁcant reduction in  variceal  bleeding  (not  categorized  as  GV  or  EV), 
incidence of hepatic encephalopathy and mortality were increased signiﬁcantly. 
126
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With the advent of other therapeutic options, and considering the reduction in 
survival, primary prophylactic shunt surgery is not recommended. Bleeding GV 
were treated by selective shunt surgery in one study of 30 patients with good 
liver function. In this study only 6 of the patients had cirrhosis (Child’s A or B) 
and the remainder had portal vein thrombosis or portal fibrosis. Bleeding was 
controlled in 87% (26/30) of cases.
127
 Two patients (7%) died (both had 
cirrhosis) and 2 patients developed shunt thrombosis. In the context of 
prevention of rebleeding, again little specific GV information exists. 
 
Clearly data on the role and efficacy of shunt surgery in patients with GV is 
lacking.  Moreover, the role of shunt surgery in patients with already existing 
spontaneous GRS, so common in GV patients, is not known.  In  a RCT 
published by Roberto et al showed that a subgroup  of  patients  with  good liver  
function,  DSRS  with  a  correct  portal-azygos disconnection  more  effectively  
prevents  variceal rebleeding than ES.  
 
BSG guidelines suggest that shunt surgery should be considered as an 
alternative to TIPS for prevention of GV rebleeding or as second-line treatment 
of refractory acute GV bleeding.
89
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The proposed algorithm for the treatment of Gastric varices   
 
 
 
 
 
Figure-5 Proposed simple algorithm for the management of gastric 
varices. 
 EVO-Endoscopic variceal obturation , BO-EIS- Balloon occluded 
endoscopic injection sclerotherapy. 
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To conclude, primary GV are found in approximately 20% of patients with 
PHT, and a further 10% to 20% of PHT patients will develop GV after 
endoscopic therapy of EV. Accurate classification of GV is essential in 
determining the optimal management of these patients.  GOV1 should be treated 
as for EV, whereas fundal varices do not respond well to therapeutic modalities 
used in EV. 
GOV1 have a low risk for hemorrhage, but the risk for bleeding from fundal 
varices can be as high as 65% within 1 year, comparable with the risk for EV 
bleeding. GV bleeding tends to be more profuse and to require more 
transfusions. A PPG of ≥12 mm Hg is not required for GV bleeding to occur 
and a large proportion (35%) bleed below this threshold, probably related to the 
high incidence of spontaneous gastrorenal shunts among GV patients. 
 The optimum acute and long-term management of GV has not been determined 
and the Reston–Baveno group have highlighted the need for RCTs for various 
GV treatment options. Endoscopic variceal obliteration has a proven track 
record in treating acute GV bleeding and should be used as first-line treatment 
of acute fundal GV bleeding, whereas other treatment modalities need further 
evaluation. 
 TIPS is a valuable adjunct to management of acute refractory or recurrent GV 
bleeding, but its role in managing patients with a PPG of ≤12mm  Hg  and  its  
appropriateness  in  patients  with  advanced liver disease remains to be 
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clarified. A number of radiologic or combination endoscopic-radiologic 
techniques have been pioneered in Japan and need further trials. 
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MATERIALS AND METHODS 
 
It is a prospective study conducted between April 2010 and October 2011 where 
consecutive patients with the diagnosis of cirrhosis, NCPF and EHPVO 
undergoing oesophagogastroduodenoscopy (OGD) scopy as a routine 
evaluation and for upper gastrointestinal bleeding were included. Patients with 
cirrhosis and NCPH are subjected to endoscopy in which if there are gastric 
varices, they are included in this study. 
If the patient diagnosed to have cirrhosis and NCPH who had already undergone 
this investigation and found to have gastric varices are also included. Grading of 
the varices and diagnosing the fundal varices are carried out by experts in 
endoscopy technique. Among the 1083 patients who underwent OGD scopy, 81 
patients were found to have gastric varices and those were included in the study. 
A non bleeder was defined as any patient without a history of hematemesis or 
melena. 
 
A written consent was obtained from all the patients. Institute ethical committee 
has approved the study.  All patients with gastric varices were included in the 
study. All the patients had baseline investigations such as Complete blood 
count, Liver function test, Prothrombin time, International normalized ratio, 
Renal function test, HBsAg, Anti-HCV and ultra sonogram. Cirrhosis was 
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diagnosed by clinical, imaging and biochemical values. EHPVO and NCPF 
have been diagnosed by ultra sonogram and Portal vein Doppler study. Baseline 
demographic details such as age, gender, literacy, socio economic status, 
alcohol intake, smoking, religion and occupation were collected.  
 
A detailed history about the upper gastrointestinal bleeding was obtained from 
all the patients such as age at the time of diagnosis, duration of illness, cause of 
portal hypertension, index bleed , subsequent bleed with dates, volume of blood 
vomiting, presence of liver cell failure feature at the time of bleed, use of 
Sengstaken Blackmore tube to arrest bleeding, use of vasopressors drugs, 
application of endoscopic sclerotherapy, endoscopic variceal ligation and glue, 
surgery details in case of failure of endotherapy and outcome after the bleed. 
 
A detailed clinical examination was also performed in all patients which 
includes pallor, jaundice, pedal edema, fever, asterixis, clubbing, cyanosis , 
presence of liver cell failure features such as Parotidomegaly, Gynaecomastia, 
Spider angioma, Dupuytran’s contarcture , Palmar erythema, Testicular atrophy 
in males and on per abdomen examination abdominal veins, liver and spleen 
enlargement and ascites. Per rectal examination, proctoscopy and examination 
of other systems was also done.  
48 
 
 
Upper gastrointestinal endoscopy and grading of the varices have been done in 
all patients. Grading of varices was done by using Sarin’s classification. In his 
classification, four types of gastric varices have been described.  
1. GOV1- Extend 2 to 5 cm below the gastroesophageal junction and are in 
continuity with esophageal varices 
2. GOV2 - Gastroesophageal varices  are in the cardia and fundus of the 
stomach and in continuity with esophageal varices 
3. IGV1 -  Varices that occur in the fundus of the stomach in the absence of 
esophageal varices are called isolated gastric varices type 
4. IGV2 -   Varices that occur in the gastric body, antrum, or pylorus 
Exclusion Criteria: 
1. Patients with only esophageal varices 
2. Child- Turcotte-Pugh score >10 
3. Patients with diagnosis other than Cirrhosis, NCPF and EHPVO. 
Patients presented with bleed were admitted in the hospital and appropriate 
resuscitative measures have been done including the use of SBT tube, use of 
octreotide, endoscopy therapy and surgery. Glue injection to obliterate the 
49 
 
varices in suitable patients. The patients are followed after treatment for the 
varices and if they will have subsequent bleed, they are admitted again to 
assess the nature of the fundal varices.  
 
Further course of the illness is also observed carefully. Follow up endoscopy 
was done regularly initially at 3
rd
 month and later at 6 months intervals. 
Patients were followed up minimum for a period of 3 months. During the 
follow up outcome of the patient was monitored.  Patients with uncontrolled 
bleeding and from remote places where endoscopic therapy is inaccessible 
were given the option to undergo surgical treatment if they are willing, to 
prevent recurrent bleeding in future. Propranolol therapy was continued in all 
patients as a primary as well as for secondary prophylaxis. 
 
Statistical analysiss 
Quantitative data were expressed in Mean and Standard deviation. Qualitative 
data were given in frequencies with their percentage. The association between 
various factors like age, gender, literacy, per capita income, alcohol 
consumption, aetiology of portal hypertension, index bleed, subsequent bleed, 
treatment given to bleed, clinical examination details and type of varices were 
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analyzed by using Pearson Chi square test/ student independent test as 
appropriate. P value less than 0.05 was taken as statistically significant. 
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OBSERVATION AND RESULTS 
A total of 1083 patients underwent upper gastro intestinal endoscopy during the 
study period. 81 patients had gastroesophageal varices and those were taken for 
analysis. Mean age of the patient is 41.23 ± 15.4 years. The aetiology for the 
gastroesophageal varices was: 
1)  Cirrhosis in 49.4%.  
2)  Extrahepatic portal vein obstruction in 27.2%. 
3)  Non cirrhotic portal fibrosis in 23.5%. 
 
Figure-1. Graphical representation of various aetiologies for gastric varices. 
Among the 81 patients, (Table-1) 75 (92.6%) patients had history of upper 
gastrointestinal bleeding and 6 (7.4%) patients had no history of bleeding. 
Subsequent bleed was observed in 58% (47) of the patients who has bled 
initially. 4 (4.9%) patients had bleed in the form of melena. All other patients 
(77) developed hematemesis during the index bleed. 
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Table-1.Demographic characteristics of the study population 
              Characteristics    n (%) 
Total No of cases 81 
Male 50(61.8%) 
Female 31(38.2%) 
Mean age ( Years)  41.23± 15.4 
Literacy 
status 
Yes  68 (84%) 
No  13 (16%) 
Per capita income ≤ 5000 74(91.3%) 
≥5000 7(8.7%) 
                 Aetiology of portal hypertension  
Cirrhosis 40 (49.4%) 
EHPVO 22 (27.2%) 
NCPF 19 (23.5%) 
Bleeder  75(92.6%) 
Non bleeder  6(7.4%) 
Outcome  Alive  74(91.4% 
Dead 7(8.6%) 
HBsAg positive 4(4.9%) 
Anti-HCV positive 3(3.75%) 
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Table-2.Bleed details 
GOV1 40(49.4%) 
GOV2 14(17.3%)    
IGV1 14(17.3%) 
IGV AND ESOPHAGEAL VARICES 12(14.8%) 
GOV1&2 1(1.2%) 
Index bleed cases 75(92.6%) 
Subsequent bleed cases 47(58%)     
Transfusions requirement 71(87.7%) 
Mean volume of blood given (L) 2.28  
Rectal varices  1(1.2%) 
 
Among the bleeders (Table-2) blood transfusion required in 87.7 % of the 
patients. The mean volume of units of blood given to the bleeding patients was 
2.28L. The number of patients underwent surgery for the bleeding episodes 
were 19 (23.5%).  
Rectal varix was seen in only one patient. GOV 1 was the commonest type 
which was seen in 40% of patients. Index bleed was present in 92.6% patients 
and subsequent bleed was seen in 58% of patients. 
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Table-3 Characteristics of bleeders and non bleeders  
Characteristics  Bleeder n (%) 
n=75 
Non bleeder 
n (%) n=6 
P value٭ 
Age (mean) 40.8 44.8 0.306 
Gender     
      Male 48 1 0.197 
      Female 27 5 
Type of gastric varices    
      GOV1 37 3 0.701 
      GOV2 13 1 0.636 
      IGV1 12 2 0.782 
  IGV &      Esophageal Varices 12 Nil  --- 
      GOV1&2 1 Nil  --- 
Aetiology of portal 
hypertension 
   
      Cirrhosis 35 5 0.193 
      NCPF 19 Nil  0.105 
      EHPVO 21 1 0.184 
Hepatic encephalopathy 14 8 0.307 
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Table-4 Index and subsequent bleed  
Characteristics Index bleed (P value)  Subsequent bleed (P value) 
Alcohol consumption 0.423 0.017 
Age at diagnosis 0.235 0.002 
Quantity of bleed 0.001 0.003 
Cause of PHT 0.193 0.005 
Duration of illness 0.452 0.001 
Follow up  0.023 0.001 
No.of Transfusions 0.001 0.001 
SBT 0.266 0.006 
EVL 0.046 0.001 
EST 0.080 0.001 
Surgery  0.159 0.008 
 
Table-4 compares the characteristics of index bleed and subsequent bleed with 
significance of the variables between the two. Quantity of bleed, follow up, No. 
of transfusions and EVL has got significant p value in both groups. Alcohol 
consumption and other parameters have significant p value in subsequent bleed. 
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Table-5 Mean value of the blood investigations 
Variables Mean  Standard deviation 
Total Count 6081.48 3382.31 
Haemoglobin 7.92 2.45 
Platelets 112575.31 92737.55 
Sugar 118.12 57.15 
Urea 28.0 15.49 
Creatinine 0.8623 0.2999 
Prothrombin time 18.05 5.25 
INR 1.54 2.44 
Total Bilirubin 2.23 2.71 
Conjugated Bilirubin 1.34 1.92 
Albumin 3.01 0.626 
Globulin 3.1 0.83 
Aspartate transaminase 48.65 29.09 
Alanine transaminase 37.95 26.33 
Serum alkaline 
phosphatase 
197.95 172.92 
 
Table-6 Complications  
        Complications  Total No. of cases n (%) 
Ascites  34 (42) 
Hepatic encephalopathy 14(17.2) 
Spontaneous bacterial peritonitis 4(4.9) 
Hepatorenal syndrome 2(2.5) 
Coagulopathy  15(18.5) 
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Figure-2 Distribution of type of varices in various aetiologies 
The type of varices commonly seen in cirrhosis (Figure-2) is GOV1, in EHPVO 
IGV1 is more frequently seen and GOV2 is mostly in NCPF.  
 
 
 
Figure- 3. Frequency of bleeding with different type of gastric varices 
The patients with GOV2 had more number of bleed episodes and severe bleed 
when compared to other types (Figure-3) 
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Table – 7 Treatment details 
 Characteristics   n (%) 
Pharmacotherapy with Octreotide 74(91.3) 
Sengstaken Blackmore tube 13(16) 
Endoscopic variceal sclerotherapy 26(32.1) 
Endoscopic variceal ligation 45(55.6) 
Glue injection 22(27.2) 
Surgery  Devascularization 
with splenectomy 
2(2.46) 
Shunt surgery 17(20.9) 
 
 
There is no significant difference between the bleeders and non-bleeders with 
regards to age (p=0306), gender (p=0.197), type of gastric varices- OGV1 
(p=0.701), OGV2 (p=0.636), IGV1 (p=0.782), aetiology of portal hypertension-
Cirrhosis (p=0.193), NCPF (p= 0.106) and EHPVO (p= 0.184).   
The index bleed parameters (Table-4) such as quantity of bleed (p=0.001), 
follow up in months (p=0.023), no of transfusions (p=0.001), EVL(0.046) had 
significant p value in index bleed group 
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Variables such as alcohol consumption (p=0.017), age at diagnosis (p=0.001), 
quantity of bleed(P=0.003), cause of PHT(P=0.005), duration of illness 
(p=0.001), follow up in months (p=0.001), No. of transfusions(p=0.001), 
EVL(p=0.001), EST(p=0.001) and surgery(p=0.008) had significant p value in 
subsequent bleed group. 
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DISCUSSION 
 
Gastric varices are common in all types of portal hypertension. Primary gastric 
varices were seen up to 20 % in patients with portal hypertension.
12
 The 
pathogenesis of portal hypertension influences the prevalence of gastric varices. 
Gastric varices were more common in segmental portal hypertension due to 
EHPVO than in generalized portal hypertension due to cirrhosis.
14
 This is 
probably due to more direct transmission of increased portal pressure to the 
short gastric and posterior gastric varices in EHPVO. In our study the 
prevalence of gastric varices is 7.5%. 
 
Gastric varices were approximately five times more common in bleeders than in 
non bleeders. This indicates that the gastric varices develop at a more advanced 
stage of portal hypertension.
12
 The most common type is GOV1, constitutes 
75% of all primary varices. In our study we have encountered of GOV1 varices 
in 49.4% patients. Other workers have also found GOV1 to be the most 
common type of gastric varix .
15
 
 
GOV2 constituted in 14(17.3%) patients. IGV1 was also observed in 14 
(17.3%) patients. Watanabe et al found them in 3% of their patients.
15
 IGV1 and 
esophageal varices were simultaneously seen in 12 patients. These varices 
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develop because of dilatation of short gastric and posterior gastric varices in 
patients with EHPVO 
128
 or because of direct anastomotic veins between the 
gastric and retroperitoneal veins in patients with cirrhosis.   Only one patient 
had GO1 and GOV2 in combination. In our study only one patient had colonic 
varices in the form of rectal varices. Table -8 shows the incidence of gastric 
varices in different aetiologies.
12  
Table-8 Study by Sarin et al. 
Pathogenesis 
of PHT 
GOV1 (%) GOV2 (%) IGV1 (%) IGV2 (%) Total (%) 
Cirrhosis 
n=301 
38(12.6) 16(5.3) 3(1) 8(2.7) 65(21.6) 
NCPF 
n=115 
16(13.9) 10(8.7) 2(1.7) 7(6.1) 35(30.4) 
EHPVO 
n=117 
29(24.8) 5(4.3) 4(3.4) 7(6.0) 45(38.5) 
HVOO n=35 2(5.7) -- -- -- 2(5.7) 
Total 85(14.9) 31(5.5) 9(1.6) 22(3.9) 147(20.9) 
Our study 40(49.4%) 14(17.3%) 14(17.3%) Nil  68(80%) 
 
According to Sarin et al, the common type of varices observed was GOV1 and 
it was seen in more number of cirrhotic patients. 
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Another study by Khalid et al (Table-9) showed the similar frequency of cases 
in each type of gastric varices except for GOV1&2. 
Table-9 
 
Regarding the treatment details considered in our study, vasopressor therapy 
with octreotide has been administered in all 81 patients. Sengstaken Blackmore 
tube was used in 13(16%) patients. Endoscopic variceal sclerotherapy and 
endoscopic variceal ligation were applied in 32.1% and 55.6% of patients. Glue 
injection was given to 22(27.2%) patients and 19 patients were referred for 
surgery. Table – 10, shows the few randomized trials of endoscopic treatment. 
In all these studies the gastroesophageal obliteration therapy was the major 
mode of treatment.
80
  
 
 
Type of varices Khalid et al Our study 
GOV1 (%) 78(35) 40(49.4) 
GOV2 (%) 56(25) 14(17.3) 
IGV1 (%) 59(27) 14(17.3) 
IGV2 (%) 6(3) Nil  
GOV1&2(%) 14(6) 1(1.2) 
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Table-10 
 
In 17 patients, proximal splenorenal shunt (PSRS) was performed as per 
institute policy. All these patients were subjected for splenectomy also. 2 
patients have undergone devascularisation with splenectomy. In a randomized 
control trial by Roberto Santambrogio et al, it was concluded that in a sub group 
of patients with good liver function, DSRS with a correct portal- azygos 
disconnection more effectively prevents variceal rebleeding than endoscopic 
sclerotherapy with N-Butyl-2-Cyanoacrylate.
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Author Classification  
GOV1/GOV2/IGV1 
Treatment  
Sarin et al (2002) 0/8/28 GVS(n=17) 
GVO(n=20) 
Tan et al(2006) 53/25/19 GVL(n=48) 
GVO(n=49) 
Lo et al(2007) 36/33/0 TIPS(n=35) 
GVO(n=37) 
Mishra et al(2010) 0/all GOV2 or IGV1 GVO(n=33) 
β –blocker(n=34) 
Our study 40/14/14 GVO=22,GVL=45 
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In our study, most number of bleed has occurred in GOV2 type (44.4%), which 
was followed by GOV1 in 14 (17.2%) patients.   In a study by Sarin et al, 
12 
GOV1 patients had more bleeding incidence. 
   
The re bleeding rate was low in patients treated with N-butyl 2-Cyanoacrylate 
(NBC). Among the 22 patients 7 patients had no rebleeding and 7 patients had 
only one episode of bleeding. This is being similar to the study published by 
Khalid Mumtaz et al, in her study the rate for primary haemostasis with NBC is 
consistent with the reported rate of 90 %- 97% in other studies.
13,28,111
 
Table-11 
 
Mortality related to bleeding from gastric varices in a series by Sarin et al 
12
 was 
45%. (Table-11) Trudeau and Pindiville 
130
 reported 55% mortality after GV 
bleeding. In our study totally 7 patients (8.6%) expired. 6 of them were bleeders 
and 1 of them was non bleeder. This non bleeding death was due to hepatic 
encephalopathy.  Among the death, GOV2 patients had higher mortality. The 
low mortality rate in our study might be due to short duration of follow up. 
 Author Mortality (%) 
Sarin et al 45 
Trudeau and Pindiville 55 
Our study 8.6% 
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SUMMARY 
In the present study, 
1) The prevalence of gastric varices is 7.5% among the various aetiologies. 
2)  The commonest type of gastroesophageal varices is GOV1 which is 
followed by GOV2 and IGV1 which is well correlated   with various 
studies. 
3) Index bleed is seen in 92.6% of patients and subsequent bleed is seen in 
58% of the patients. 
4) Among the aetiology, cirrhosis is the most common cause and EHPVO is 
the next common cause for gastroesophageal varices.  
5) There is no significant difference between the bleeders and nonbleeders 
with regards to age, gender, type of gastric varices- GOV1, GOV2, IGV1, 
aetiology of portal hypertension (Cirrhosis, NCPF and EHPVO), and 
complication such as hepatic encephalopathy.   
6) Nineteen patients (19/81 - IGV1-14, OGV2-5) have undergone surgical 
treatment to arrest the recurrent bleeding. 
7) The index bleed parameters such as quantity of bleed, follow up in 
months, no of transfusions, EST and EVL had significant p value in 
index bleed group. 
66 
 
8) The subsequent bleed parameters - alcohol consumption, age at diagnosis, 
quantity of bleed, cause of PHT, duration of illness, follow up in months, 
no. of transfusions, SBT, EVL, EST and surgery had significant p value 
in subsequent bleed group. 
9) In our study mortality is less (8.6%), when compared to other studies.  
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CONCLUSION 
In conclusion, the results of our study confirm that the prevalence of 
gastroesophageal varices was low but within the range when compared with 
various studies.  
The type of the varices in Our study tallies with the international 
classification and the common type is GOV1 as denoted by many studies. 
GOV1 is relatively have a benign course and requires treatment only in the 
form of gastric variceal sclerotherapy if they bleed. 
For most GOV2 varices, endoscopic variceal obliteration therapy with N-
Butyl 2- Cyanoacrylate is quite useful in arresting the bleeding and 
achieving the variceal obliteration.  
Although endoscopic therapy was effective in treating some patients with 
IGV1 varices, surgery was required in significant no. of patients to prevent 
re bleeding.  
In our study, the surgery was contemplated for such patients and also for 
other type of gastric varices because those patients were from far remote 
places where the immediate endoscopic intervention may not be feasible 
always. 
IGV2 cases were less in Our study and it might require long term follow up 
to identify such patients.  
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Because the gastric varices have the potential to cause severe upper GI 
bleeding, its recognition is very important to manage the cases appropriately.  
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